Clinical Trials

308 enrolled

Advanced Solid Tumor

NCT06596473 2026-06-04

A Study of BG-C477 in Participants With Advanced Solid Tumors

310 enrolled

Advanced Solid Tumors

NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3 Completed

404 enrolled

Advanced Malignancies

NCT05981703 2026-06-03

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

217 enrolled

Advanced Solid Tumor

NCT06427941 2026-06-03

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

392 enrolled

GastrointestinalOther solid neoplasmThoracic

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

NCT06585488 2026-06-03

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Phase 1 Terminated

47 enrolled

Metastatic Solid Tumors

NCT07414836 2026-06-03

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

84 enrolled

Advanced Solid Tumor

NCT07557914 2026-06-03

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes

32 enrolled

Diabetes Mellitus, Carcinoma, Hepatocellular

NCT04539444 2026-06-02

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Phase 3 Not yet recruiting

18 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT06914011 2026-06-02

MRD2START

172 enrolled

Esophageal Neoplasms

NCT07619937 2026-06-02

Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma

31 enrolled

Cholangiocarcinoma

NCT05542342 2026-06-01

SITISVEAL

16 enrolled 14 charts

Dermatologic

Melanoma

NCT07136077 2026-06-01

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

20 enrolled

Phase 3 Active not recruiting

Colorectal Neoplasms, Neoplasm, Residual

NCT05211232 2026-05-29

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

450 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06010303 2026-05-28

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

118 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07609121 2026-05-27

Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC

160 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07601737 2026-05-22

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 3 Active not recruiting

182 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05152147 2026-05-19

HERIZON-GEA-01

920 enrolled

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT05431270 2026-05-19

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phase 1/2 Recruiting

40 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT07331155 2026-05-18

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

110 enrolled

Advanced Solid Tumour

NCT07390383 2026-05-13

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

110 enrolled

Advanced Solid Tumour

NCT04746924 2026-05-12

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Phase 3 Terminated

669 enrolled 27 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT07413354 2026-05-12

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

94 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Hepatocellular

NCT05661955 2026-05-11

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

113 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma

NCT06487858 2026-05-11

A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors

Phase 1 Terminated

42 enrolled

Solid Tumor

NCT07554521 2026-05-11

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

30 enrolled

Esophageal Squamous Cell Carcinoma

NCT07019675 2026-05-08

A Study of SKB518 in Patients With Lung Cancer

192 enrolled

Lung Neoplasms

NCT06745908 2026-05-05

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

Phase 3 Recruiting

507 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07040956 2026-05-04

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

98 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06349837 2026-05-01

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

24 enrolled

Solid Tumor

NCT07030140 2026-05-01

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

38 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT07561060 2026-05-01

TNTIT

Phase 1/2 Recruiting

50 enrolled

Rectal Neoplasms

NCT07561983 2026-05-01

BEACON-Lung

39 enrolled

Unresectable Stage III Non-small Cell Lung Cancer

NCT06897579 2026-04-28

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

Phase 2 Terminated

40 enrolled

Phase 2/3 Not yet recruiting

Extensive Stage Small Cell Lung Cancer

NCT07554456 2026-04-28

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

90 enrolled

Phase 1 Not yet recruiting

Esophageal Squamous Cell Carcinoma

NCT07453875 2026-04-27

TRIUNITE06

9 enrolled

Colorectal Neoplasms

NCT06536868 2026-04-24

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

40 enrolled

Phase 3 Active not recruiting

Small Cell Lung Carcinoma

NCT03967977 2026-04-23

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

420 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT03736889 2026-04-22

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

200 enrolled

Phase 1 Enrolling by invitation

MSI-H/dMMR Solid Tumors

NCT07353294 2026-04-22

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

12 enrolled

Lymphatic Metastasis

NCT05519865 2026-04-20

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

118 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07416474 2026-04-20

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Phase 3 Recruiting

574 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07502300 2026-04-20

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)

562 enrolled

Small Cell Lung Carcinoma

NCT06233981 2026-04-17

Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis

30 enrolled

Phase NA Not yet recruiting

Carcinoma, Hepatocellular

NCT07535840 2026-04-17

A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma

25 enrolled

Phase 2 Active not recruiting

Carcinoma, Hepatocellular

NCT05635708 2026-04-15

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07528274 2026-04-14

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03957590 2026-04-13

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Phase 3 Completed

370 enrolled 17 charts

Esophageal Squamous Cell Carcinoma

NCT07518706 2026-04-09

Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin

60 enrolled

Phase 1 Active not recruiting

Carcinoma, Hepatocellular

NCT06422520 2026-04-06

A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

120 enrolled